EUVIMEDScopri EUVIMED
Open access · CC BY 4.0

iPSC ‐Derived iNK Progenitors Engraft and Generate NK Cells in Unconditioned and Autologous Immune Humanized Mice

Min Zhang, Zhiqian Wang, Yanhong Liu, Leqiang Zhang, Fangxiao Hu, Chengxiang Xia, Mengyun Zhang, Tongjie Wang, Qitong Weng, Hanmeng Qi, Yanping Zhu, Lijuan Liu and 3 more

Cell Proliferation · 2026-07-10

DOI: 10.1111/cpr.70261 ↗

At a glance

Journal article in Cell Proliferation, published online on 2026-07-10. Written by Min Zhang and 14 co-authors. Institution: Chinese Institutes for Medical Research, Beijing, China. 21 references. The full text is freely available (open access, CC BY 4.0). Funded by: the National Natural Science Foundation of China, the National Key R&D Program of China, the Noncommunicable Chronic Diseases-National Science and Technology Major Project.

AbstractDati bibliograficiCiteRelated studies

Abstract (original language)

NK cells exhibit inherently short persistence in vivo. Allo‐NK cells trigger host immune rejection in immune‐competent patients. Lymphodepletion is a conventional approach for mitigating allogeneic rejection of therapeutic NK cells, which brings host immune suppression and infection risks. To address these problems, we test the concept of engrafting iNK progenitor (iNKP) cells derived from human induced pluripotent stem cells (iPSC) to achieve generating iNK cells in vivo in unconditioned host‐immune humanised mice without the requirement for prior lymphodepleting chemotherapy or total body irradiation. Our results showed that a single low‐dose infusion of iNKP cells successfully engrafted and continuously produced mature iNK cells in unconditioned B‐NDG hIL15 mice. Furthermore, the iPSC‐derived iNKP cells survived in the presence of autologous PBMC‐humanised mice and generated mature iNK cells. This study provides evidence that autologous iPSC‐derived iNKP cells have the application potential for treating the same individual without the preceding necessity of lymphodepletion.

Authors and institutions

  • Chinese Institutes for Medical Research, Beijing, China.
  • The Beijing Key Laboratory of Tumor Resistance Mechanism and Clinical Translation, Affiliated with the Chinese Institutes for Medical Research, Beijing, China.
  • State Key Laboratory of Organ Regeneration and Reconstruction, Institute of Zoology, Chinese Academy of Sciences, Beijing, China.
  • University of Chinese Academy of Sciences, Beijing, China.
  • Beijing Institute for Stem Cell and Regenerative Medicine, Beijing, China.
  • Department of Hematology, Beijing Chao-Yang Hospital, Capital Medical University, Beijing, China.

ORCID profiles: Dehao Huang, Hong-Hu Zhu, Jinyong Wang

Funding

  • the National Natural Science Foundation of China
  • the National Key R&D Program of China
  • the Noncommunicable Chronic Diseases-National Science and Technology Major Project
  • National Natural Science Foundation of China
  • National Key Research and Development Program of China

Cite

APA

Zhang, M., Wang, Z., Liu, Y., Zhang, L., Hu, F., Xia, C., Zhang, M., Wang, T., Weng, Q., Qi, H., Zhu, Y., Liu, L., Huang, D., Zhu, H. H., & Wang, J. (2026). iPSC ‐Derived iNK Progenitors Engraft and Generate NK Cells in Unconditioned and Autologous Immune Humanized Mice. Cell Proliferation. https://doi.org/10.1111/cpr.70261

Vancouver

Zhang M, Wang Z, Liu Y, Zhang L, Hu F, Xia C, et al. iPSC ‐Derived iNK Progenitors Engraft and Generate NK Cells in Unconditioned and Autologous Immune Humanized Mice. Cell Proliferation. 2026. doi:10.1111/cpr.70261

BibTeX
@article{Zhang2026,
  author = {Zhang, Min and Wang, Zhiqian and Liu, Yanhong and Zhang, Leqiang and Hu, Fangxiao and Xia, Chengxiang and Zhang, Mengyun and Wang, Tongjie and Weng, Qitong and Qi, Hanmeng and Zhu, Yanping and Liu, Lijuan and Huang, Dehao and Zhu, Hong-Hu and Wang, Jinyong},
  title = {iPSC ‐Derived iNK Progenitors Engraft and Generate NK Cells in Unconditioned and Autologous Immune Humanized Mice},
  journal = {Cell Proliferation},
  year = {2026},
  doi = {10.1111/cpr.70261}
}
Start for free →